Thermo Fisher Scientific has introduced the Applied Biosystems™ MagMAX™ Sequential DNA/RNA kit to enable clinical and translational researchers to conduct comprehensive DNA and RNA genomic analysis and streamline detection of genetic abnormalities found in hematological malignancies.  

The MagMAX Sequential DNA/RNA kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications. This integration merges two separate workflows into one sequential process, accommodating up to 15,000 white blood cells per microliter without the need for an additional red blood cell lysis step. By simplifying the workflow and reducing the need for multiple processes, it enhances overall lab productivity and helps reduce costs.  

Research and clinical applications of hematological cancer like leukemia, lymphoma and myeloma is increasingly important, as approximately 10% of new cancer cases each year are hematological, according to the Leukemia & Lymphoma Society. To understand and identify the cancer-causing genetic alterations that cause hematological cancer, researchers need to be able to efficiently isolate nucleic acids from hematological samples. 

“When researching blood cancer, it’s essential for scientists to extract the maximum amount of information from minimal sample volumes. Through this product innovation, we are supporting researchers and clinicians by providing a solution that allows for high-quality sequential isolation of genomic DNA and total RNA from a single blood or bone marrow sample,” said Kevin Lowitz, vice president, sample preparation, Thermo Fisher Scientific. “We’re proud to help streamline comprehensive genomic analysis, helping improve efficiency and preserve precious samples.”